LMB763
Total Payments
$930,145
Transactions
32
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $28,410 | 9 | 0 |
| 2019 | $42,776 | 12 | 1 |
| 2018 | $770,415 | 8 | 1 |
| 2017 | $88,544 | 3 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $930,145 | 32 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF LMB763 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | Novartis Pharmaceuticals Corporation | $873,002 | 1 |
| A RANDOMIZED PATIENT AND PHYSICIAN BLINDED PLACEBO CONTROLLED 24 WEEK STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF LMB763 IN PATIENTS WITH DIABETIC NEPHROPATHY | Novartis Pharmaceuticals Corporation | $55,148 | 0 |
| A RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF LMB763 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,995 | 1 |
Top Doctors Receiving Payments for LMB763
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Juan, PR | $927,925 | 29 |
| , MD | Diagnostic Radiology | Rochester, NY | $2,220 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $930,145
- Total Doctors 1
- Transactions 32
About LMB763
LMB763 is a drug associated with $930,145 in payments to 1 healthcare providers, recorded across 32 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $28,410 was paid across 9 transactions to 0 doctors.
The most common payment nature for LMB763 is "Unspecified" ($930,145, 100.0% of total).
LMB763 is associated with 3 research studies, including "A RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF LMB763 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH" ($873,002).